Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation

Bastion, 1997, Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients, J Clin Oncol, 15, 1587, 10.1200/JCO.1997.15.4.1587 Montoto, 2007, Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma, J Clin Oncol, 25, 2426, 10.1200/JCO.2006.09.3260 Al-Tourah, 2008, Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma, J Clin Oncol, 26, 5165, 10.1200/JCO.2008.16.0283 Conconi, 2012, Incidence, risk factors and outcome of histological transformation in follicular lymphoma, Br J Haematol, 157, 188, 10.1111/j.1365-2141.2012.09054.x Ghesquières, 2006, Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis, J Clin Oncol, 24, 5234, 10.1200/JCO.2006.07.5671 Reddy, 2012, Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation, Clin Lymphoma Myeloma Leuk, 12, 406, 10.1016/j.clml.2012.07.003 Guirguis, 2014, Survival of patients with transformed lymphoma in the rituximab era, Ann Hematol, 93, 1007, 10.1007/s00277-013-1991-y Villa, 2013, Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation, Ann Oncol, 24, 1603, 10.1093/annonc/mdt029 Villa, 2013, Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group, J Clin Oncol, 31, 1164, 10.1200/JCO.2012.44.0693 Ban-Hoefen, 2013, Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database, Br J Haematol, 163, 487, 10.1111/bjh.12570 Ban-Hoefen, 2012, High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era, Leuk Lymphoma, 53, 830, 10.3109/10428194.2011.631637 Eide, 2011, High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study, Br J Haematol, 152, 600, 10.1111/j.1365-2141.2010.08519.x Armand, 2013, Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era, Br J Haematol, 160, 608, 10.1111/bjh.12176 Smith, 2009, High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma, Leuk Lymphoma, 50, 1625, 10.1080/10428190903128652 Hamadani, 2008, High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma, Eur J Haematol, 81, 425, 10.1111/j.1600-0609.2008.01146.x Sabloff, 2007, A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma, Biol Blood Marrow Transplant, 13, 956, 10.1016/j.bbmt.2007.04.009 Andreadis, 2005, Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma, Bone Marrow Transplant, 36, 955, 10.1038/sj.bmt.1705178 Blaker, 2014, High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era, Leuk Lymphoma, 55, 2319, 10.3109/10428194.2013.871632 2010, Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank, Clin Epidemiol, 2, 51 D' Amore, 1994, Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group, J Clin Oncol, 12, 1673, 10.1200/JCO.1994.12.8.1673 Gang, 2012, R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group, Ann Oncol, 23, 147, 10.1093/annonc/mdr058 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Lossos, 2011, Transformation of follicular lymphoma, Best Pract Res Clin Haematol, 24, 147, 10.1016/j.beha.2011.02.006 Montoto, 2011, Transformation of indolent B-cell lymphomas, J Clin Oncol, 29, 1827, 10.1200/JCO.2010.32.7577 Carlotti, 2009, Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone, Blood, 113, 3553, 10.1182/blood-2008-08-174839 Sehn, 2011, Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP, J Clin Oncol, 29, 1452, 10.1200/JCO.2010.33.3419 Chung, 2007, Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index, Blood, 110, 1278, 10.1182/blood-2007-01-070300 Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 Friedberg, 2005, Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy, Hematology Am Soc Hematol Educ Program, 329, 10.1182/asheducation-2005.1.329 Cartron, 2002, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, 99, 754, 10.1182/blood.V99.3.754 Golay, 2000, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis, Blood, 95, 3900, 10.1182/blood.V95.12.3900.012k14_3900_3908 Jazirehi, 2007, Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy, Cancer Res, 67, 1270, 10.1158/0008-5472.CAN-06-2184 Macor, 2007, In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab, Cancer Res, 67, 10556, 10.1158/0008-5472.CAN-07-1811 Treon, 2001, Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies, J Immunother, 24, 263, 10.1097/00002371-200105000-00011 Olejniczak, 2008, Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression, Clin Cancer Res, 14, 1550, 10.1158/1078-0432.CCR-07-1255